Changes in serum receptor activator of nuclear factor-κB ligand, osteoprotegerin, and interleukin-6 levels in patients with glucocorticoid-induced osteoporosis treated with human parathyroid hormone (1-34).
The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
Changes in biochemical markers of bone turnover following intermittent injections of human (h)PTH (1-34) suggest that bone formation is initially favored over bone resorption. hPTH (1-34) is also known to influence osteoclast maturation and activity through modulation of osteoblast-derived cytokines, such as receptor activator of nuclear factor-kappaB ligand (RANKL), osteoprotegerin (OPG), IL-6, and IL-6 soluble receptor (IL-6sR). In this experiment, we investigated the changes in serum levels of soluble RANKL (sRANKL), OPG, IL-6, and IL-6sR in patients with glucocorticoid-induced osteoporosis treated with hPTH (1-34). Fifty-one postmenopausal women with glucocorticoid-induced osteoporosis were randomized to receive 12 months of 400 U hPTH (1-34) ( approximately 40 microg) daily and standard hormone replacement therapy, or hormone replacement therapy alone. Serum levels of sRANKL, OPG, IL-6, and IL-6sR were measured at baseline, 1 month, and every 3 months thereafter for a total of 24 months. hPTH (1-34) caused a rapid and significant increase in sRANKL within 1 month, and the levels remained elevated throughout the duration of therapy. IL-6 and IL-6sR increased significantly within 1 month, but returned to baseline levels more rapidly. In contrast, OPG was mildly suppressed beginning 6 months after hPTH therapy. These data support the hypothesis that hPTH (1-34) initially stimulates osteoblast maturation and function, which in turn leads to osteoclast activation and a gradual rebalancing of bone formation and resorption.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Osteoclast activity is likely to depend, at least in part, on the relative balance of RANKL and OPG.”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [93]
In the citing paper
“Intermittent PTH treatment in humans was also shown to increase serum RANKL and to reduce serum OPG (93), suggesting that OPG and RANKL might mediate the resorptive response to PTH independent of the mode of PTH administration.”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [93]
In the citing paper
“Treatment with human PTH in women receiving chronic glucocorticoid and hormone replacement therapy resulted in rapid increase in serum RANKL by 1 month and a decrease in serum OPG levels at 6 and 12 months of therapy (93).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [93]
Citations
Cites
Neer, R. M., Arnaud, C. D., Zanchetta, J. R., Prince, R., Gaich, G. A., Reginster, J.-Y., Hodsman, A. B., Eriksen, E. F., Ish-Shalom, S., Genant, H. K., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105103441904 · Cited by 4,602
Minireview: The OPG/RANKL/RANK System
Khosla, S. (2001) · Endocrinology · doi:10.1210/endo.142.12.8536 · Cited by 1,515 · cited 1×
“PTH controls bone formation and resorption primarily through modulation of the OPG/RANKL/RANK system (9).”
BackgroundBlack, D. M., Greenspan, S. L., Ensrud, K. E., Palermo, L., McGowan, J. A., Lang, T. F., Garnero, P., Bouxsein, M. L., Bilezikian, J. P., & Rosen, C. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa031975 · Cited by 1,174
The Effects of Parathyroid Hormone, Alendronate, or Both in Men with Osteoporosis
Finkelstein, J. S., Hayes, A., Hunzelman, J. L., Wyland, J. J., Lee, H., & Neer, R. M. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa035725 · Cited by 829
Hofbauer, L. C., Gori, F., Riggs, B. L., Lacey, D. L., Dunstan, C. R., Spelsberg, T. C., & Khosla, S. (1999) · Endocrinology · doi:10.1210/endo.140.10.7034 · Cited by 794
Lindsay, R., Nieves, J., Formica, C., Henneman, E., Woelfert, L., Shen, V., Dempster, D., & Cosman, F. (1997) · The Lancet · doi:10.1016/s0140-6736(97)02342-8 · Cited by 749
Lane, N. E., Sanchez, S., Modin, G. W., Genant, H. K., Pierini, E., & Arnaud, C. D. (1998) · Journal of Clinical Investigation · doi:10.1172/jci3914 · Cited by 529
Self-citationInterleukin-6 and interleukin-11 support human osteoclast formation by a RANKL-independent mechanism
Kudo, O., Sabokbar, A., Pocock, A., Itonaga, I., Fujikawa, Y., & Athanasou, N. A. (2003) · Bone · doi:10.1016/s8756-3282(02)00915-8 · Cited by 477
Lee, S.-K., & Lorenzo, J. A. (1999) · Endocrinology · doi:10.1210/endo.140.8.6887 · Cited by 464
Horwood, N. J. (1998) · Endocrinology · doi:10.1210/en.139.11.4743 · Cited by 461
Cited by
Glucocorticoid-induced osteoporosis: pathophysiology and therapy
Canalis, E., Mazziotti, G., Giustina, A., & Bilezikian, J. P. (2007) · Osteoporosis International · doi:10.1007/s00198-007-0394-0 · Cited by 1,114
“According to the concept of the “anabolic window”, PTH rapidly and powerfully stimulates osteoblast function [112].”
BackgroundKearns, A. E., Khosla, S., & Kostenuik, P. J. (2008) · Endocrine Reviews · doi:10.1210/er.2007-0014 · Cited by 824
Extraintestinal manifestations in inflammatory bowel disease
Danese, S. (2005) · World Journal of Gastroenterology · doi:10.3748/wjg.v11.i46.7227 · Cited by 373
Glucocorticoid-induced osteoporosis: an update
Mazziotti, G., Angeli, A., Bilezikian, J. P., Canalis, E., & Giustina, A. (2006) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2006.03.009 · Cited by 362
Osteoblast physiology in normal and pathological conditions
Neve, A., Corrado, A., & Cantatore, F. P. (2011) · Cell and Tissue Research · doi:10.1007/s00441-010-1086-1 · Cited by 331
“In vitro (Rogers and Eastell 2005) and in vivo (Buxton et al. 2004) human studies have confirmed these data.”
BackgroundOsteoprotegerin and RANKL regulate bone resorption, density, geometry and strength.
KOSTENUIK, P. (2005) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2005.06.005 · Cited by 281
The Pathogenesis, Epidemiology and Management of Glucocorticoid-Induced Osteoporosis
van Staa, T. P. (2006) · Calcified Tissue International · doi:10.1007/s00223-006-0019-1 · Cited by 260
Rogers, A., & Eastell, R. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-0794 · Cited by 215
“The effect of intermittent PTH therapy on serum OPG has been investigated in women with glucocorticoid-induced osteoporosis (107).”
BackgroundSafety of osteoanabolic therapy: A decade of experience
Capriani, C., Irani, D., & Bilezikian, J. P. (2012) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1800 · Cited by 145
Teriparatide: A Review of its Use in Osteoporosis
Blick, S. K. A., Dhillon, S., & Keam, S. J. (2008) · Drugs · doi:10.2165/0003495-200868180-00012 · Cited by 126
The RANKL/OPG system and bone mineral density in patients with chronic liver disease
Moschen, A. R., Kaser, A., Stadlmann, S., Millonig, G., Kaser, S., Mühllechner, P., Habior, A., Graziadei, I. W., Vogel, W., & Tilg, H. (2005) · Journal of Hepatology · doi:10.1016/j.jhep.2005.05.034 · Cited by 129
“c Time between OPG/sRANKL and BMD assessment was 7 (28) [0–112] days detection a mouse anti-human OPG monoclonal antibody (mAb) was purchased from Imgenex (San Diego, CA).”
BackgroundMethodMendonça, M. L., Pereira, F. A., Nogueira‐Barbosa, M. H., Monsignore, L. M., Teixeira, S. R., Watanabe, P. C. A., Maciel, L. M. Z., & de Paula, F. J. A. (2013) · BMC Endocrine Disorders · doi:10.1186/1472-6823-13-1 · Cited by 112
“Also, serum OC (CV = 5.6%; Quidel, San Diego, CA, USA), 25-OH-D (CV= 7.2%; Immunodiagnostic System, Fountain Hills, AZ), OPG (CV= 5.6%; Quidel, San Diego, CA, USA) and RANKL (CV = 6.8%; Biomedica, Austria) and urinary DPD (CV= 6.7%; Quidel, San Diego, CA, USA), were measured by enzyme immunoassay.”
BackgroundInfluentialGentleman, E., Stevens, M. M., Hill, R. G., & Brauer, D. S. (2012) · Acta Biomaterialia · doi:10.1016/j.actbio.2012.10.043 · Cited by 108
Komarova, S. V. (2005) · Endocrinology · doi:10.1210/en.2004-1642 · Cited by 92
“First PTH was modeled to induce increases only in the RANKL/OPG ratio, an effect shown to follow both intermittent and continuous PTH administration (14, 35).”
BackgroundThe “Sunshine Deficit” and Cardiovascular Disease
Wallis, D. E., Penckofer, S. M., & Sizemore, G. W. (2008) · Circulation · doi:10.1161/circulationaha.107.713339 · Cited by 94
Iwasaki-Ishizuka, Y., Yamato, H., Nii‐Kono, T., Kurokawa, K., & Fukagawa, M. (2005) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfh876 · Cited by 86
“[15] examined the effect of intermittent PTH injection in patients with low turnover osteoporosis.”
Abe, Y., Takahata, M., Ito, M., Irie, K., Abumi, K., & Minami, A. (2007) · Bone · doi:10.1016/j.bone.2007.06.025 · Cited by 90
“In vivo and clinical studies, however, demonstrated that intermittent PTH treatment also upregulates bone resorbing activity concurrently with bone formative activity [4,9,32].”
BackgroundParathyroid Hormone as an Anabolic Skeletal Therapy
Rubin, M. R., & Bilezikian, J. P. (2005) · Drugs · doi:10.2165/00003495-200565170-00005 · Cited by 82
Effect of parathyroid hormone on experimental tooth movement in rats
Li, F., Li, G., Hu, H., Liu, R., Chen, J., & Zou, S. (2013) · American Journal of Orthodontics and Dentofacial Orthopedics · doi:10.1016/j.ajodo.2013.05.010 · Cited by 58
RANK ligand inhibition with denosumab for the management of osteoporosis
Lewiecki, E. M. (2006) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.6.10.1041 · Cited by 65
“Osteotropic hormones and cytokines are capable of regulating the expression of RANKL and OPG in human-derived osteoblast cell lines [45].”
BackgroundThe Circadian Rhythm of Osteoprotegerin and Its Association with Parathyroid Hormone Secretion
Joseph, F., Chan, B. Y., Durham, B. H., Ahmad, A. M., Vinjamuri, S., Gallagher, J. A., Vora, J. P., & Fraser, W. D. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1832 · Cited by 55
Wagner, D., & Fahrleitner‐Pammer, A. (2010) · Wiener Medizinische Wochenschrift · doi:10.1007/s10354-010-0818-x · Cited by 60
“These results indicate that hPTH [1–34] initially stimulates osteoblast maturation and function, which in turn leads to osteoclast activation and a gradual rebalancing of bone formation and resorption [ 57 , 58].”
Nakchbandi, I. A., Lang, R., Kinder, B. K., & Insogna, K. L. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1645 · Cited by 54
Glucocorticoid-Induced osteoporosis: clinical and therapeutic aspects
Mazziotti, G., Giustina, A., CANALIS, E. M., & Bilezikian, J. P. (2007) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302007000800028 · Cited by 54
Cunningham, J. (2006) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006050427 · Cited by 47
“PTH given as a low-dosage daily injection that is sufficient to elevate the plasma PTH concentration to two to three times the upper limit of normal (transiently) clearly is a potent anabolic agent (97) that is capable of increasing BMD and reducing fracture risk in patients with osteoporosis (98).”
BackgroundGlucocorticoid-Induced Osteoporosis: Mechanisms and Therapeutic Approach
Devogelaer, J. (2006) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2006.09.001 · Cited by 45
Chi, G., Qiu, L., Ma, J., Wu, W., & Zhang, Y. (2023) · Journal of Orthopaedic Surgery and Research · doi:10.1186/s13018-023-04179-5 · Cited by 58
RANKL inhibition for the management of patients with benign metabolic bone disorders
Anastasilakis, A. D., Toulis, K. A., Pοlyzos, S. A., & Terpos, E. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780903048929 · Cited by 39
“In human studies, sOPG has been reported not specifically altered in teriparatide-treated postmenopausal women with osteoporosis [124] and decreased in glucocorticoid-induced osteoporosis [142].”
BackgroundOhwada, R., Hotta, M., Sato, K., Shibasaki, T., & Takano, K. (2007) · Endocrine Journal · doi:10.1507/endocrj.k07-034 · Cited by 36
Denosumab: an investigational drug for the management of postmenopausal osteoporosis
Lewiecki, M. E. (2008) · Biologics · doi:10.2147/btt.s2082 · Cited by 37
“Osteotropic hormones and cytokines are have been observed to regulate expression of RANKL and OPG in human-derived osteoblast cell lines (Hofbauer et al 1999).”
BackgroundLossdörfer, S., Yildiz, F., Götz, W., Kheralla, Y., & Jäger, A. (2009) · Clinical Oral Investigations · doi:10.1007/s00784-009-0263-7 · Cited by 30
“These data are corroborated by Buxton et al. [ 9 ] and support the hypothesis that PTH (1-34) initially stimulates osteoblast maturation and function, which in turn leads to osteoclast activation and a gradual rebalancing of bone formation and resorption.”
ResultGlucocorticoid-induced osteoporosis and parathyroid hormone.
Carpinteri, R., Porcelli, T., Mejia, C., Patelli, I., Bilezikian, J. P., CANALIS, E. M., Angeli, A., Giustina, A., & Mazziotti, G. (2010) · PubMed · Cited by 35
Anastasilakis, A. D., Goulis, D. G., Pοlyzos, S. A., Gerou, S., Pavlidou, V., KOUKOULIS, G. N., & Avramidis, A. (2008) · European Journal of Endocrinology · doi:10.1530/eje-07-0528 · Cited by 29
Bowsher, R. R., & Sailstad, J. M. (2008) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2008.09.026 · Cited by 27
Developments in the scientific understanding of osteoporosis
Lane, N. E., & Yao, W. (2009) · Arthritis Research & Therapy · doi:10.1186/ar2656 · Cited by 32
“However, when the PTH receptor was located on the osteoblast, we determined that PTH treatment augmented the maturation of osteoblasts to make bone, but also stimulated osteoblasts to produce RANKL that augmented osteoclastogenesis [67].”
BackgroundSelf-citationZhu, X., Luo, J. D., Chen, X., Wang, J., Wang, G., Li, H., Xu, Y., Feng, J., & Tu, H. (2008) · Translational research · doi:10.1016/j.trsl.2008.05.003 · Cited by 26
Management of glucocorticoids-induced osteoporosis: role of teriparatide
Migliaccio, S., Brama, M., & Malavolta, N. (2009) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s3940 · Cited by 30
Trevisani, V. F. M., Riera, R., Imoto, A. M., Saconato, H., & Atallah, Á. N. (2008) · Sao Paulo Medical Journal · doi:10.1590/s1516-31802008000500007 · Cited by 24
Teriparatide treatment complicated by malignant myeloma
Koski, A.-M., Sikiö, A., & Forslund, T. (2010) · BMJ Case Reports · doi:10.1136/bcr.01.2010.2681 · Cited by 22
“Although significant differences between the mechanisms in the development of malignant myeloma and the positive effects on increased bone formation by teriparatide exists, some of the biochemical components participating during teriparatide treatment are also involved in development of malignant myeloma. In malignant…”
Parathyroid hormone and its effects on dental tissues
Aggarwal, P., & Zavras, A. I. (2011) · Oral Diseases · doi:10.1111/j.1601-0825.2011.01850.x · Cited by 22
Guo, Y., Yuan, W., Wang, L., Shang, M., & Peng, Y. (2010) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfq521 · Cited by 21
“In patients with glucocorticoid-induced osteoporosis, treatment with PTH caused a rapid and significant increase in the circulating levels of nuclear factor-κB (NF-κB) ligand, the receptor activator for NF-κB ligand (RANKL), IL-6 and IL-6 soluble receptor (IL-6sR) [13].”
BackgroundAlemzadeh, R., & Kichler, J. (2016) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2015.0099 · Cited by 20
“Furthermore, increasing PTH concentrations have been found to increase expression of NF-kB, an important regulator of proinflammatory gene expression, in both in vivo and in vitro settings.(44,45) Similar to a previous study by the authors, the serum PTH level and PTH:25(OH)D ratio were positively correlated with FM a…”
Hurley, M. M., Yao, W., & Lane, N. E. (2005) · Osteoporosis International · doi:10.1007/s00198-005-1998-x · Cited by 20
“As described previously, 51 postmenopausal women, 50– 82 years of age and with osteoporosis (T-score £ 2.5 at the lumbar spine and/or hip), were enrolled in the study [8, 9, 10 ].”
BackgroundMethodResultInfluentialSelf-citationLossdörfer, S., Stier, S., Götz, W., & Jäger, A. (2005) · Journal of Periodontal Research · doi:10.1111/j.1600-0765.2005.00838.x · Cited by 24
Heckt, T., Keller, J., Peters, S., Streichert, T., Chalaris, A., Rose‐John, S., Mell, B., Joe, B., Amling, M., & Schinke, T. (2016) · Bone · doi:10.1016/j.bone.2016.08.016 · Cited by 21
Cellular Actions of Parathyroid Hormone
Kousteni, S., & Bilezikian, J. P. (2008) · Elsevier eBooks · doi:10.1016/b978-0-12-373884-4.00049-5 · Cited by 19
Marques, M. R., dos Santos, M. C. L. G., da Silva, A. F., Nociti, F. H., & Barros, S. P. (2009) · Journal of Periodontal Research · doi:10.1111/j.1600-0765.2008.01186.x · Cited by 16
Johansson, H., Skripitz, R., & Aspenberg, P. (2008) · Journal of Bone and Joint Surgery - British Volume · doi:10.1302/0301-620x.90b3.19544 · Cited by 15
Dore, R. K. (2013) · Patient Preference and Adherence · doi:10.2147/ppa.s31067 · Cited by 17
Feng, Y., Zhou, M., Zhang, Q., Liu, H., Xu, Y., Shu, L., Zhang, J., Miao, D., & Ren, Y. (2015) · British Journal Of Nutrition · doi:10.1017/s0007114514004309 · Cited by 13
Wu, Z., Yan, D., Xie, Z.-J., Weng, S., Zhou, Q., Li, H., Bai, B.-L., Boodhun, V., Shen, Z., Tang, J., et al. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.10.039 · Cited by 13
Treatment of glucocorticoid-induced osteoporosis
Mazziotti, G., Giustina, A., CANALIS, E. M., & Bilezikian, J. P. (2009) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x09343222 · Cited by 13
“The remodelling system is associated with an upregulation of osteoblast derived cytokines such as RANKL, IL-6 and a suppression of osteoprotegerin [Canalis et al. 2007b; Buxton et al. 2004 ].”
BackgroundChen, X., Song, I., Dennis, J. E., & Greenfield, E. M. (2007) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.070122 · Cited by 12
“Etoposide induces apoptosis by blocking DNA repair,((40)) whereas dexamethasone is more physiologically and pharmacologically relevant because endogenous glucocorticoids regulate osteoblast apoptosis((41)) and long-term glucocorticoid therapy induces osteoporosis.((42)) In contrast, overexpression of PKI decreases the…”
BackgroundLane, N. E. (2007) · Current Opinion in Rheumatology · doi:10.1097/bor.0b013e32816a9436 · Cited by 12
Self-citationForslund, T., Koski, A.-M., Koistinen, A., & Sikiö, A. (2008) · Clinical Medicine Case Reports · doi:10.4137/ccrep.s1026 · Cited by 11
“In osteoblast cell cultures PTH related peptide 1–34 (PTHrP1-34) stimulate the expression of interleukin-6 (IL-6) [2,4].”
BackgroundPeriodontal response to nonsurgical accelerated orthodontic tooth movement
Öner, F., & Kantarcı, A. (2025) · Periodontology 2000 · doi:10.1111/prd.12623 · Cited by 14
Malik, A. K., Khaldoyanidi, S. K., Auci, D. L., Miller, S. C., Ahlem, C. N., Reading, C. L., Page, T., & Frincke, J. M. (2010) · PLoS ONE · doi:10.1371/journal.pone.0013566 · Cited by 10
Spotlight on Teriparatide in Osteoporosis†
Blick, S. K. A., Dhillon, S., & Keam, S. J. (2009) · BioDrugs · doi:10.2165/00063030-200923030-00006 · Cited by 8
Lu, C., Chen, Y., Zhang, B., Chen, Y., Bai, F., & Chen, D. (2017) · Clinical Interventions in Aging · doi:10.2147/cia.s140900 · Cited by 8
Adami, S. (2008) · Current Medical Research and Opinion · doi:10.1185/03007990802518130 · Cited by 8
Bilezikian, J. P., & Rubin, M. R. (2006) · Elsevier eBooks · doi:10.1016/b9-78-012088-5/62650-039x · Cited by 8
Lane, N. E. (2009) · Elsevier eBooks · doi:10.1016/b978-1-4160-3285-4.10092-0 · Cited by 7
Self-citationNew perspectives on parathyroid hormone therapy
Lane, N. E., & Morris, S. A. (2005) · Current Opinion in Rheumatology · doi:10.1097/01.bor.0000166383.73153.cf · Cited by 5
Self-citationGlucocorticoids, Inflammation, and Bone
Ng, K. W., & Martin, T. J. (2012) · Springer eBooks · doi:10.1007/978-1-4471-2745-1_7 · Cited by 5
Lane, N. E. (2016) · Elsevier eBooks · doi:10.1016/b978-0-323-31696-5.00101-7 · Cited by 5
Self-citationENA Actimineral Resource A restores bone loss and bone quality in ovariectomized rats
Hee, S., Hwa, S.-Y., Jeong, W., Lee, J., Kim, H.-J., Lee, I., & Jeong, K. (2006) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-006-9269-5 · Cited by 4
“This dye can bind select to calcium salts (2 mol/mol of dye) [28].”
BackgroundOsteoporosis: yesterday, today and tomorrow
Lane, N. E. (2011) · Lara D. Veeken · doi:10.1093/rheumatology/ker147 · Cited by 4
Self-citationPapassava, M., Nakou, I., Siomou, E. C., Cholevas, V., Challa, A. S., & Tzoufi, M. S. (2019) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2019.05.029 · Cited by 4
Trabecular bone volume and osteoprotegerin expression in uremic rats given high calcium
Rianthavorn, P., Ettenger, R. B., Salusky, I. B., & Kuizon, B. D. (2010) · Pediatric Nephrology · doi:10.1007/s00467-010-1611-1 · Cited by 3
“Similar findings were noted in humans receiving intermittent PTH treatment: serum RANKL level increased while the serum OPG level decreased [14].”
ResultLane, N. E. (2013) · Elsevier eBooks · doi:10.1016/b978-1-4377-1738-9.00101-8 · Cited by 3
Self-citationOsteoprotegerin Serum Levels in Primary Hyperparathyroidism and Changes Following Surgery
Minisola, S., Cipriani, C., Piemonte, S., Colangelo, L., Pepe, J., & Romagnoli, E. (2014) · Hormone and Metabolic Research · doi:10.1055/s-0033-1363278 · Cited by 3
Cassez, R., Cortet, B., Bouvard, B., Theis, D., Potey, C., Manier, S., Paccou, J., & Philippoteaux, C. (2026) · Archives of Osteoporosis · doi:10.1007/s11657-026-01693-x · Cited by 2
Multiple Myeloma Case Developed During the Use of the Teriparatide
Erdemir, Z., Ünübol, A. İ., Ünübol, M., Aktekin, E. E., Yavaşoğlu, İ., & Güney, E. (2022) · Turkish Journal of Osteoporosis · doi:10.4274/tod.galenos.2021.24582 · Cited by 2
Treatment of Male Osteoporosis with Parathyroid Hormone
Girotra, M., Cosman, F., & Bilezikian, J. P. (2010) · Elsevier eBooks · doi:10.1016/b978-0-12-374602-3.00055-9 · Cited by 1
Aspectos terapéuticos de la osteoporosis
Díez‐Pérez, A. (2007) · Medicina Clínica · doi:10.1157/13113776 · Cited by 1
Circulating RANKL is not a reliable biomarker for bone loss in primary hyperparathyroidism
Grigorie, D., Şucaliuc, A., Neacşu, E., Militaru, R., Diaconescu, A., & Ivan, M. (2013) · Bone Abstracts · doi:10.1530/boneabs.1.pp488
“a gradual decrease toward baseline after 6 mo and become non-significantly different after 3 mo of discontinuation [4].”
BackgroundReview Developments in the scientific understanding of osteoporosis
Lane, N. E., & Yao, W. (2009)
Self-citationParathyroid Hormone for the Treatment of Osteoporosis: The Science and the Therapy
Lane, N. E. (2006) · Elsevier eBooks · doi:10.1016/b978-0-323-03437-1.50026-9
Self-citation(2006) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/01.gco.0000233944.74672.e0
Metadata
- Authors
- Buxton, E. C., Yao, W., & Lane, N. E.
- Affiliations
- University of California, San Francisco (US)
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2004-07-01
- Volume
- 89
- Issue
- 7
- Pages
- 3332-3336
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2042509724
- Cited by
- 79
- References
- 29
- Citations by year
- 2026: 1 · 2025: 1 · 2023: 1 · 2022: 1 · 2019: 1 · 2018: 1 · 2017: 1 · 2016: 3 · 2015: 1 · 2014: 1 · 2013: 5 · 2012: 3
- FWCI
- 3.43
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5r01dk046661-05)
- National Institute of Diabetes and Digestive and Kidney Diseases (DK 46661-07)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (K24AR048841, AR048841-01)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Nephrology › Parathyroid Disorders and Treatments
- Keywords
- glucocorticoid-induced osteoporosis, human parathyroid hormone (1-34), RANKL, osteoprotegerin, interleukin-6, bone turnover markers, postmenopausal women, hormone replacement therapy, osteoclast activation, osteoblast maturation, bone formation and resorption
- MeSH terms
- Aged, Aged, 80 and over, Carrier Proteins, Female, Follow-Up Studies, Glucocorticoids, Glycoproteins, Humans, Membrane Glycoproteins, Middle Aged, Osteoporosis, Parathyroid Hormone, Peptide Fragments, Solubility, Time Factors, Interleukin-6, Receptors, Tumor Necrosis Factor, Receptors, Cytoplasmic and Nuclear, Receptors, Interleukin-6, Osteoprotegerin, RANK Ligand, Receptor Activator of Nuclear Factor-kappa B
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.